Research programme: norepinephrine reuptake inhibitors - Supernus Pharmaceuticals
Latest Information Update: 16 Jul 2016
At a glance
- Originator Unknown
- Developer Supernus Pharmaceuticals
- Class 3-ring heterocyclic compounds; Anorectics; Behavioural disorder therapies; Drug withdrawal therapies; Imidazoles; Isoindoles; Sleep disorder therapies; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Adrenergic receptor antagonists; Dopamine uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Attention-deficit-hyperactivity-disorder in USA (PO)
- 29 Jul 2009 Early research in Attention-deficit hyperactivity disorder in USA (unspecified route)